MedTrace Logo

The Effects of Different Lipid Emulsions on the Adipokines in Critically Ill Patients With Sepsis

NCT04711564 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-01-15

No results posted yet for this study

Summary

Intravenous lipid emulsions contain a number of biologically active ingredients, but the most important are fatty acids. Different fatty acids can affect a number of different physiological processes in different ways in critically ill patients. Adipose tissue can play an important role in metabolic changes of critical illnesses and in adaptation to stress through structural as well as functional changes Although it is known that serum adipokine and cytokine response changes in critical sepsis patients, the factors affecting these changes and the metabolic consequences of these changes are not well defined. The aim of this study was to evaluate the effects of intravenous lipid emulsions on serum adipokine and cytokine levels in patients with sepsis. Secondly, this is to determine the adipokine and cytokine kinetics in the sepsis process and their relationship with mortality in patients with sepsis.

Conditions

Interventions

OTHER

Olive oil-based intravenous fat emulsions

Parenteral nutrition planned according to the requirements of the patients is given for ten days.

OTHER

Soybean-based intravenous fat emulsions

Parenteral nutrition planned according to the requirements of the patients is given for ten days.

Sponsors & Collaborators

  • Turkish Society of Clinical Enteral and Parenteral Nutrition

    collaborator OTHER

  • Karadeniz Technical University

    lead OTHER

Principal Investigators

  • Melda Kangalgil, MSc · Karadeniz Technical University

  • Ahmet Oguzhan Kucuk, MD · Karadeniz Technical University

  • Asiye Ozdemir, MD · Karadeniz Technical University

  • Süleyman Caner Karahan, MD · Karadeniz Technical University

  • Umitcan Ok, MD · Karadeniz Technical University

  • Hatice Bozkurt Yavuz, MD · Karadeniz Technical University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-29
Primary Completion
2020-03-25
Completion
2020-04-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04711564 on ClinicalTrials.gov